ArticleThe Lancet. Haematology2016
The collaborative network approach: a new framework to accelerate Castleman's disease and other rare disease research.
Article in The Lancet. Haematology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Article
- Recent Advances in Organ-on-Chips Integrated with Bioprinting Technologies for Drug Screening.Advanced healthcare materials · 2023Review
- How we manage idiopathic multicentric Castleman disease.Clinical advances in hematology & oncology : H&O · 2022Article
- A framework for fibrolamellar carcinoma research and clinical trials.Nature reviews. Gastroenterology & hepatology · 2022Review
- ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder.Cell reports. Medicine · 2020Article
- Analysis of Clinical Characteristics, Pathological Changes and Changes of Interleukin-6 (IL-6) and C-Reactive Protein (CRP) in Children with Castleman's Disease.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- HHV-8-negative multicentric Castleman disease presenting as a crescentic immune complexes membranoproliferative glomerulonephritis.BMJ case reports · 2020Article
- Quantitative analysis of a rare disease network's international contact database and E-repository provides insights into biobanking in the electronic consent era.Orphanet journal of rare diseases · 2019Article
- Importance of Participant-Centricity and Trust for a Sustainable Medical Information Commons.The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics · 2019Article
- Hiv and Lymphoma: from Epidemiology to Clinical Management.Mediterranean journal of hematology and infectious diseases · 2019Review
- Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.Hematology. American Society of Hematology. Education Program · 2018Review
- Review
- International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.Blood · 2018Article
- Perspective From the 5th International Pemphigus and Pemphigoid Foundation Scientific Conference.Frontiers in medicine · 2018Article
- TAFRO syndrome: current perspectives.Journal of blood medicine · 2018Review
- Tissue chips - innovative tools for drug development and disease modeling.Lab on a chip · 2017Review
- TAFRO syndrome: New subtype of idiopathic multicentric Castleman disease.Bosnian journal of basic medical sciences · 2017Review
- Article
- Importance of an International Registry for and Collaborative Research on Esophageal Atresia.Frontiers in pediatrics · 2017Article
- Tissue Chips to aid drug development and modeling for rare diseases.Expert opinion on orphan drugs · 2016Article
Corrections and comments
- Comment on
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
27063967What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.